Abstract | The myelin sheath wraps large axons in both the CNS and the PNS, and is a key determinant of efficient axonal function and health. Myelin is targeted in a series of diseases, notably multiple sclerosis (MS). In MS, demyelination is associated with progressive axonal damage, which determines the level of patient disability. The few treatments that are available for combating myelin damage in MS and related disorders, which largely comprise anti-inflammatory drugs, only show limited efficacy in subsets of patients. More-effective treatment of myelin disorders will probably be accomplished by early intervention with combinatorial therapies that target inflammation and other processes-for example, signaling pathways that promote remyelination. Indeed, evidence suggests that such pathways might be impaired in pathology and, hence, contribute to the failure of remyelination in such diseases. In this article, we review the molecular basis of signaling pathways that regulate myelination in the CNS and PNS, with a focus on signals that affect differentiation of myelinating glia. We also discuss factors such as extracellular molecules that act as modulators of these pathways. Finally, we consider the few preclinical and clinical trials of agents that augment this signaling.
Introduction
Most large axons in the mammalian nervous system are surrounded by a lipid-rich membrane known as the myelin sheath, which promotes rapid conduction of nerve impulses and protects against axonal damage. Myelin sheaths form during development and consist of compacted spiral wraps of membrane that are supplied by oligo dendrocytes in the CNS and Schwann cells in the PNS (Box 1 and Figure 1 ). These myelinating glia and their target axons form intimate units, with the glia and axons regulating each other's phenotype through the reciprocal exchange of signals (Boxes 2-4).
During development, glia provide survival signals to neurons, define the molecular domains of the axolemma, and determine the diameter of axons. 1, 2 In turn, axons provide signals that regulate the proliferation, survival and differentiation of glia, as well as myelin formation. [3] [4] [5] In adulthood, myelinating glia maintain axolemmal organiza tion, axonal diameter and neuronal health, while axons maintain glial differentiation and myelin integrity. 2 At least in the PNS, axonal damage alters these main tenance signals and initiates an active program of Schwann cell dedifferentiation, which probably facilitates myelin reabsorption. 6 Multiple diseases target myelin, including multiple sclero sis (MS) and hereditary leukodystrophies in the CNS, and Guillain-Barré syndrome and hereditary demyeli nating neuropathies in the PNS. 7 In general, the degree of disability observed in myelin dis orders co rrelates best with the level of associated axonal damage. 8, 9 In most disorders, axonal damage is recognized after myelin damage, suggesting that signals from glia or myelin to axons might be altered by disease. New evidence from studies of MS and of globoid (Krabbe) leukodystrophy indicates that axonal damage might occur contemporaneously with myelin damage in some conditions. 8, 10 Thus, loss of non-myelin-related glial signals or, even, addition of toxic signals from glia might damage axons. Finally, non-myelin-forming Schwann cells are not innocent bystanders. Such cells respond to nearby demyelination by proliferating, which impairs the relationship of these cells with the small-caliber axons that subserve pain sensation. 11 Taken together, these observations call into question which cell type (that is, myelinating or non myelinating glial cells or neurons) is the most appropriate target for therapy in diseases of myelin.
Treatment of the most common myelin disorders is limited to anti-inflammatory therapies, which can have notable adverse effects. 12 Where can we find other therapeutic targets beyond inflammation? Remyelination occurs in both the CNS and PNS after damage and might provide adjunctive targets for therapy that is aimed at limit ing destruction of myelin and axons. 13 In MS, remyelina tion occurs in the CNS after initial myelin damage, but fails after multiple episodes of demyelination. This failure of remyelination subsequently leads to augmented axonal degeneration and progressive disability. 13 Thus, early intervention with treatments that promote remyelination might slow the progression of MS. The proliferation and migration of oligodendroglial precursor cells (OPCs) near MS plaques has been the focus of much work, 13 but failure of OPCs to differentiate has also been recognized. This inability to differentiate might reflect inhibitory influences, or destruction or dysfunction of axons, which are an important source of differentiation signals for OPCs. 13 A starting point for consideration of how differentiation of OPCs might be promoted during repair is the assumption that remyelination depends on signals similar to those that occur in developmental myelination. Indeed, oligodendrocyte precursors or immature Schwann cells are likely to recapitulate differentiation when these cells remyeli nate axons. 13 Here, we review the various signals that are crucial to the axoglial inter action ( Figure 1 ). As the molecular basis of glial support of axons is poorly understood, 4 the main focus of this Review is on the axon to glia signaling pathways that might promote differentiation of glia and, hence, the formation or maintenance of myelin. We also discuss the extent to which developmental studies can guide remyelination therapies, and provide an overview of the limited number of preclinical and clinical trials that have tested such treatments.
Axolemma-based signaling pathways
Glial myelination can be influenced by axonal contact, [14] [15] [16] [17] diameter [18] [19] [20] or electrical activity. [21] [22] [23] [24] [25] These findings suggest that signals originating from the axonal membrane regulate myelination (Box 2; Figures 2 and 3 ).
neuregulins and erbB receptors
In the PNS, the neuregulin family of proteins and their receptors, which belong to the erbB family of tyrosine kinase receptors (heterodimeric erbB-2-erbB-3 receptors in Schwann cells), have emerged as important regulators of most aspects of Schwann cell development. 26 The neu regulins are encoded by at least four genes, of which NRG1 is the best characterized. 27, 28 NRG1 encodes multiple isoforms, all containing an epidermal growth factorlike domain. Most isoforms are shed, but some remain anchored in the membrane. 28 In the PNS, neuregulin 1 type III, which is expressed on the axonal membrane, is a key determinant of whether a Schwann cell will form myelin and, if so, how thick the myelin sheath will become. 29, 30 The potency of neuregulin 1 type III for inducing myelination was demonstrated in cultured superior cervical ganglion neurons, which normally have small-diameter unmyelinated axons. When this neuregulin was ectopically expressed in such neurons, the associated Schwann cells responded by changing fate and myelinating axons, although the axons retained their small diameter. 30 In the CNS, the role of neuregulins in myelination remains controversial. Several studies have reported that rodents deficient in either neuregulin 1 or erbB receptors had impaired oligodendrocyte differentiation, proliferation, survival and myelination. [31] [32] [33] [34] [35] These findings suggested that neuregulins might be important in CNS myelination. Brinkmann et al., however, reported that mice lacking all neuregulin 1 isoforms or both erbB-3 and erbB-4 receptors showed normal CNS myelination during development. Interestingly, these researchers also showed that neu regulin 1 overexpression in the CNS of transgenic mice
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Neuregulin-induced signals are clearly important for myelination during development; however, the involvement of these signals in myelin maintenance, damage or remyelination is unclear. The partial reduction of erbB-2 function in Schwann cells of adult transgenic mice had no effect on myelin, suggesting that neuregulin signals might be dispensable for maintenance of the myelin sheath in the PNS. 41 Activation of the erbB receptors in myelinating neuron-Schwann cell cocultures or on nerve injury induced demyelination. 42, 43 Such activation might have involved shed neuregulin 1 ligands rather than membrane-anchored neuregulin 1 type III. Interestingly, and in agreement with a possible role for erbB receptors in CNS remyelination, overexpression of erbB-1 in a mouse model of demyelination promoted oligodendrocyte di fferentiation and remyelination. 44 Box 1 | Myelin formation in mammals rodents Before birth, oligodendroglial precursors emerge from the ventral and dorsal neural tube and migrate throughout the forming brain and spinal cord. Perinatally, these cells differentiate and, mostly after birth, go on to myelinate segments of multiple axons. 156 Before birth, Schwann cell precursors arise from the neural crest, and migrate out with extending neurites to form embryonic peripheral nerves. Immature Schwann cells differentiate in the perinatal period and begin to form myelin mostly after birth. Unlike oligodendrocytes, Schwann cells only myelinate a single segment of one axon. 5 
Humans
Before birth, oligodendroglial and Schwann cell precursors follow a similar developmental pattern to that observed in rodents. At the time of birth, myelination has already begun in both the PNS (spinal roots) and CNS (primarily in spinal cord, brainstem and cerebellum, but sparsely above the subcortical nuclei). 157 Myelin formation is markedly more protracted in humans than in rodents, extending over the first few years of life.
revieWS The secretases
In general, the number of growth factors is much lower than the number of biological functions that these molecules regulate. Diversification of function is achieved by altering ligands or downstream signals. For example, a growth factor can activate different signaling pathways depending on whether it is presented in a soluble or membrane-bound form. Secretases, such as 'a dis integrin and metalloprotease' (ADAM) proteins, β-secretase (β-site amyloid precursor protein cleaving enzyme 1 or BACe1) or the γ-secretase complex, all change the presentation of membrane-associated growth factors.
Many myelin-related growth factors (for example, neuregulin 1), growth factor receptors (for example, p75 neurotrophin receptor [p75 NTR ]) and Notch 1, undergo proteolytic cleavage at the axonal membrane, suggesting that this process is a common way of regulating these myelin-associated signaling molecules. Identification of the secretases involved in such cleavage and determination of their mechanisms of action could reveal important therapeutic targets for promoting remyelination.
Several ADAMs have been implicated in myelination. 45 One study showed that Adam22-null mice ex hibited hypomyelinated nerves, 46 while data from another study suggested that ADAM22 might bind leucine-rich gliomainactivated proteins, 47 which had previously been implicated in PNS myelination. 48 In addition, ADAM19 is upregulated following axonal injury and Adam19-null mice exhibit delayed remyelination. 49 Research has revealed that neuregulin 1 type III can be cleaved by BACe1, and that this process is probably regulated by the zinc metallopeptidase nardilysin. 50 In agreement with these findings, Bace1-null mice and mice lacking expression of nardilysin showed marked hypomyelination in the PNS 50, 51 and in the CNS. 50, 52 The level of hypomyelination in both strains of mutant mice was similar to the level observed in mice with a 50% reduction in neuregulin 1 type III expression. 29, 30 Taken together, the results from these studies indicate that BACe1 promotes myelination. In addition, one study has demonstrated that Bace1-null mice show impaired remyelination during regeneration following a nerve-crush injury. 53 Inhibition of γ-secretase accelerates the onset and increases the level of myelination by rat oligodendrocytes in a coculture system. 54 Moreover, data from various studies have suggested that γ-secretase might cleave neuregulin 1, 55,56 p75 NTR57 or Notch 1 58 and, hence, potentially activate multiple intracellular signaling pathways in neurons. Regulated intramembrane proteolysis, a highly conserved method of intracellular communication, seems to be an important control of downstream signals in both axons and glial cells.
The secretases have generated strong interest from pharma ceutical companies as potential therapeutic targets, because these proteases are accessible and multiple secretase inhibitors are already available. Therapeutic strate gies that target the secretases must consider the problem of specificity and, hence, collateral effects, as single secretases target multiple molecules. For example, BACe1, a potentiator of myelination, cleaves not only neuregulins but also amyloid precursor protein, which leads to the generation of the amyloid-β 42 peptide-a molecule that is probably pathogenetic in Alzheimer disease.
The AKT1 signaling pathway AKT1 (serine-threonine-specific protein kinase AKT-PKB) is emerging as an integrator of various signals that increase myelination in both the CNS and PNS (Box 3; Figures 2 and 3 ). Studies have shown that AKT1 is phosphorylated by phosphatidylinositol 3 kinase (PI3K) in response to growth factors that promote myelination, in particular neuregulin 1 type III, 30 insulin-like growth factor I (IGF-I) 59, 60 and steroids. 61 In addition, the expression of constitutively active AKT1 in mouse oligo dendrocytes led to an increase in myelination.
62
PI3K-AKT1 signaling is thought to augment myelination through activation of the kinase mammalian target of rapamycin (mTOR), as inhibition of mTOR in vivo was shown to limit myelination in the developing mouse brain. 63 The activation of mTOR induces formation of both mTORC1 and mTORC2 complexes, which in turn regulate the terminal differentiation of oligodendrocytes, as well as myelin protein and lipid expression. 64 The transcription factors targeted by the AKT1-mTOR signals have yet to be fully elucidated in oligodendrocytes, 65 although studies have identified two possible candidates, namely myelin gene regulatory factor 66 and zinc finger protein 191. revieWS transcription factor 1 (POu3F1 or Oct-6), early growth response protein 2 (eGR-2 or Krox-20) and SRY-box contain ing transcription factor 10 (SOX-10). 68 For example, in cultured mouse Schwann cells, AKT1 upregulated eGR-2-activated myelin protein P0 expression after IGF-I stimulation. 49 Conversely, eGR-2 repressed, and was repressed by, dedifferentiation factors, including SOX-2 and Notch 1. [69] [70] [71] Such reciprocal inhibition permits active, rapid dedifferentiation of Schwann cells after nerve injury, which is necessary for facilitating myelin regeneration. 70, 71 Furthermore, these data suggest that the neuregulin 1 type III-AKT1 intracellular signaling pathway could be a therapeutic target in demyelinating neuropathies where dedifferentiation genes are inappropriately expressed.
6,72
The calcineurin-nFAT signaling pathway A study in mice lacking expression of the calcineurin B1 subunit showed that, in Schwann cells, the calcineurin-NFAT (nuclear factor of activated T cells) pathway is involved in activating myelination. 73 This signaling pathway is downstream of neuregulin 1 and indepen dent of PI3K. NFAT signal transduction pathways have important roles in multiple tissues, including in the developing nervous system, where they promote axonal growth and guidance. 74 experiments involving the conditional deletion of the gene encoding calcineurin B1 in Schwann cells or in sensory neurons revealed that NFATpromoted myelina tion occurs through a mechanism that is autonomous to Schwann cells. 73 These experiments suggest a model in which activation of erbB-2-erbB-3 hetero dimers leads to increased intracellular calcium levels (via activation of phospholipase Cγ) and subsequent activation of calci neurin. In turn, calcineurin activation promotes nuclear translocation of NFATc4, which forms a complex with SOX-10 that upregulates eGR-2 transcription and myelin gene transcription. 73 nectin-like proteins Nectin-like proteins (NeCls), also known as cell adhesion molecules (CADMs), comprise five members, and have been implicated in axoglia interactions and myelination. The roles of NeCl-1-4 have been investigated in the rodent nervous system. Studies have reported that heterophilic interactions between NeCl-1 (CADM3) on the axolemma and NeCl-4 (CADM4) on Schwann cells might participate in myelination in the PNS. 75, 76 Schwann cells must polarize with axonal and basal lamina surfaces to form myelin, and NeCls have been implicated in this process. 77 Thus, NeCl-4 might interact with partitioning defective (PAR) polarity complexes, which have pre viously been implicated in PNS myelination.
78 Surprisingly, transgenic mice lacking expression of NeCl-1 displayed a mild phenotype, with no effect on PNS myelination and a developmental delay in CNS myelination. 79 Functional compensation by other NeCls 76, 80 or unrelated adhesion proteins might account for this lack of effect. notch Notch signaling is fundamental for glial cell development and myelination in both the CNS and PNS. Notch receptors comprise four members, all of which are type I transmembrane proteins. On ligand binding, Notch receptors are cleaved intracellularly by secretases. The γ-secretase complex generates an intracellular fragment, the Notch intracellular domain (NICD), which translocates to the nucleus to activate gene transcription. The ligand engaged on the Notch receptor determines whether the canonical or noncanonical signaling pathway (mediated by RBP-J or Deltex, respectively) is activated. 81 In the CNS, canonical Notch 1 ligands, which comprise members of the Delta or Jagged (Serrate) protein families, are expressed by neurons at early developmental stages. 82 Notch 1 is only expressed by oligodendrocytes. 83 In vitro 
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ATP purinergic signaling
Adenosine binds glial purinergic receptors and promotes oligodendroglial ■ differentiation 23 Axons of electrically active neurons release ATP , which stimulates the production ■ and release of leukemia inhibitory factor from astrocytes, thereby augmenting myelination by oligodendrocytes 164 ATP binds glial P2Y receptors and inhibits Schwann cell proliferation and ■ differentiation 165 Adenosine also binds the A2 ■ A receptor, which inhibits Schwann cell proliferation but not myelination and in vivo studies have shown that binding of Jagged1 to Notch 1 inhibits OPC differentiation and myelination, [83] [84] [85] [86] and that such inhibition is mediated via activation of the transcription factor hairy and enhancer of split 5 (HeS-5). 82 These findings suggest that Notch 1 is important for correct spatial and temporal differentiation of OPCs.
Jagged1 expression is downregulated in retinal ganglion cells after birth; however, in MS, this protein has been reported to be re-expressed in reactive astrocytes surrounding plaques. 82 This finding suggested that the failure of OPCs to mature near such lesions could be the result of reactivation of the Notch inhibitory pathway. In support of this assertion, HeS-5 expression has been detected in oligodendrocytes near MS plaques. 82 How much of this protein is found in the nuclei of these cells, however, remains controversial. 87 Surprisingly, in adult mice that were exposed to chemicals that induce demyelination, conditional ablation of Notch1 in oligodendrocytes did not have a marked effect on remyelination. 88 Nevertheless, one study showed that inactivation of Notch1 in mice during development led to an acceleration in oligodendroglial differentia tion. 86 ultimately, adult myelin was normal in these animals. Taken together, these results suggest that the timing of Notch 1 inhibition might be critical for achieving remyelina tion, and that Notch 1 could be a therapeutic target in myelin disorders.
Contactin-1 (also known as neural cell surface protein F3) is a putative noncanonical ligand of Notch 1 that is expressed on axons later in development than canonical ligands. This Notch ligand has been suggested to promote rather than inhibit OPC differentiation and the expression of myelin genes in the CNS. 89 Nevertheless, the observation that myelination and remyelination are accelerated but eventually normalize in mice lacking Notch1 in oligodendrocytes argues against this idea.
86,88
In the rodent PNS, Notch 1 is expressed exclusively by Schwann cells, whereas Jagged1 is present on both Schwann cells and axons. 71 Notch 1 has been shown to promote gliogenesis over neurogenesis in neural crest stem cells in vitro. 90 Furthermore, in vivo rodent studies have demonstrated that both canonical and non canonical Notch 1 pathways determine the complex activity of Notch 1 in PNS development and myelination. 71 Notch 1, via canonical signaling pathways, promotes the transition from precursor to immature Schwann cells. 71 By contrast, Notch 1 inhibits the onset of PNS myelination. Notch 1 expression is tightly down regulated by eGR-2-a transcription factor that is necessary for activating the myelinating program. 91 Moreover, the overexpression of NICD delays myelination and results in hypomyelination. The inhibitory effect of Notch 1 on myelination is thought to be mediated through noncanonical pathways, as the inhibition seems to be independent of the effects of RBP-J. Interestingly, myelination is also inhibited immediately after nerve injury, thereby allowing proper Schwann cell dedifferentiation and proliferation. Reactivation of Notch 1 expression after injury is associated with the RBP-J canonical signal. Thus, the Notch 1 pathway is differentially regulated in development and after injury. Moreover, these data relating to Notch 1 indicate that, in the PNS, the molecular events regulating myelination in development differ in part from those involved in remyelination. 71 HeS-5 and histone deacetylases HeS-5 can be regulated by Notch-independent signals in OPCs, and activation of HeS-5 can impede the differentiation of these cells during remyelination. For example, epigenetic modifications of chromatin, such as histone deacetylation, blocked the expression of inhibitory transcription factors, including HeS-5, SOX-2, inhibitor of DNA binding (ID) 2, and ID-4, and promoted myelination in a mouse model. 92 Inadequate recruitment of histone deacetylases (HDACs) to the promoters of inhibitory transcription factors results in the sustained expression of these factors, mirroring what happens in aged rodents, where remyelination is less efficient than in young rodents. 92 This finding suggests that activation of HDACs might represent a promising strategy for promoting remyelination. Paradoxically, however, use of HDAC inhibitors in animal models of inflammatory demyelination have been shown to reduce the level of demyelination and limit disability. 92, 93 One possible reason for this discrepancy is that HDAC inhibitors might act not only on oligo dendrocytes, but also on cells of the immune system or on axons. Indeed, in vitro 
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insulin-like growth factor i (igF-i)
Promotes oligodendrocyte differentiation and survival, as well as myelin ■ integrity and function 59 Administration of exogenous recombinant IGF-I to rats with experimental ■ autoimmune encephalomyelitis (EAE) closed the disrupted blood-brain barrier, reduced the number and severity of demyelinating lesions, and improved neurological function 168 
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Like platelet-derived growth factor, thyroid hormone is an instructive signal for ■ oligodendrocyte development and maturation 170 Administration of thyroxine in animal models of demyelination and ■ remyelination, such as mice with EAE or animals treated with cuprizone, has proved beneficial for remyelination 155, 171 
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In MS, semaphorins 3A and 3F are upregulated in the CNS and modulate ■ oligodendrocyte recruitment and differentiation 121 netrins Secreted molecules that are important for axonal pathfinding ■ In the CNS, the netrin receptor promotes membrane extension ■ 127 revieWS studies have shown that HDAC1 might induce axonal damage in inflammatory demyelinating diseases when the protein is exported from the nucleus to the cytoplasm of neurons. 94 This effect could be a potential confound ing factor in studies of re myelination using HDAC inhibitors.
Axoglial junction molecules
A series of protein and lipid complexes mediate the physical interaction between axons and myelinating glia. These complexes organize proteins (for example, ion channels) in the axonal and glial membranes, and maintain cell proximity to facilitate the transmission of signals that promote myelination. 1 One role for such complexes is in the segregation of voltage-gated sodium (Nav) and potassium channels at nodes of Ranvier and juxta paranodal regions, respectively. Such segregation is crucial for proper conduction of axonal impulses (Figure 1) .
The combination of functional importance and accessi bility renders the axoglial apparatus a prime pathogenetic-and also pharmacological-target. Indeed, early disaggregation of Nav, gliomedin, 95 neurofascin 96 and contactin-associated protein 97 clusters precedes demyelination in experimental allergic encephalitis (eAe) in rodents or in MS, and disaggregation of clusters is also found at the edges of chronic plaques in MS brains. 97 Disruption of ion channel clusters at nodes can produce conduction block and early functional dis ability, which accompanies demyelination. 95 Furthermore, reclusterization of channels is the first event that marks the onset of remyelination. 98 Finally, nodal and paranodal proteins are altered in genetic neuropathies, 99 emphasizing the importance of cluster di sruption as a general pathogenet ic mechanism.
Interestingly, axoglial complexes contain autoantigens that are targeted by the immune system in MS, chronic inflammatory demyelinating neuropathy and GuillainBarré syndrome. Autoantibodies against neurofascin 186, gliomedin 95 and GM1 100 (all nodal components), as well as neurofascin 155 101 (a paranodal component) have been detected in patients or animal models of disease and, in some cases, have been shown to be pathogenetic. Human autoantibodies against both axonal and glial neuro fascins directly inhibited axonal conduction when applied to rodent tissue slices. 101 Moreover, when transferred together with pathogenetic T cells, these autoantibodies exacerbated the severity of eAe in rats in a complementdependent manner. 101 Similarly, anti-GM1 antibodies bound complement proteins and disrupted Nav channel clusters in rabbit nerves. 100 Thus, therapeutic strategies aimed at limiting attacks on the axoglial apparatus or promoting its reformation could preserve the role of this apparatus in myelination and impulse conduction.
Extracellular modulators
In addition to molecules in the axolemma, secreted extracellular molecules modulate myelination, either indepen dently or in concert with neuregulins or other axonal signals (Box 3). 6, 13 The accessibility of these extracellular molecules and their potential role in promoting myelination make such molecules appealing therapeutic targets in myelin diseases. Interesting examples of such molecules are laminins, semaphorins and netrins, all of which are secreted molecules involved in axonal gu idance during development.
Laminins
Seminal work from the Bunge laboratory showed that high concentrations of laminin could induce myelination in Schwann cell-neuron cocultures in the absence of the myelination-promoting factor ascorbate. 102, 103 Integrin and dystroglycan receptors mediate the effects of laminin on the survival and differentiation of oligodendrocytes and Schwann cells. [104] [105] [106] In both cell types, laminin might cooperate with axonal neuregulin 1 to promote survival and differentiation. Adhesion of integrin α6β1 to laminin switches the neuregulin 1 response in oligodendrocytes from the promotion of proliferation to the promotion of differentiation, with only those cells in which differentiation is induced going on to survive. 106, 107 In Schwann cells, the absence of laminin impairs the phosphorylation of erbB-2 and the activation of AKT1, which is normally associated with differentiation. 111 while a laminin deficiency in dystrophic mice caused regional hypomyelination. 38, 109 Whether integrin β1 mediates these effects is controversial. expression of a dominant-negative integrin β1 in mice delayed the myelina tion of small-caliber axons. 112 However, loss of function analyses of integrin β1 in the CNS have reported either hypomyelination 113 or normal myelination and remyelination. 114 In the PNS, myelin thickness is not obviously reduced in laminin-deficient dystrophic mice, or in the absence of the laminin receptors dystroglycan or integrin α6β4. [115] [116] [117] The absence of integrin β1 arrests development before myelin formation, thereby precluding the analysis of its effects on myelination. 118 Interestingly, laminin receptors might protect against demyelination, as acute demyelination has been described in mice lacking both integrin α6β4 and dystroglycan in Schwann cells. 117 
Semaphorins
Factors other than laminins promote glial recruitment and differentiation, and could be modulated to improve remyelination. 13 Among these factors are secreted semaphorins, the co-receptors for which are present on myelinating glia. 119, 120 Semaphorins 3A and 3F have been found around active-but not chronic-demyelinated plaques in both patients with MS and mouse models of this disease. These observations led lubetzki and colleagues to suggest that semaphorins might have a role in remyelination. 121 After injury, myelinating oligodendrocytes also express semaphorin 4D, 122 which limits oligodendrocyte number 123 and promotes process collapse. 124 Finally, in neurofibromatosis 1, loss of semaphorin 4F in Schwann cells impairs axoglia communication, and restoring semaphorin 4F expression normalizes this interaction in vitro. These findings suggest a means of reducing neuro fibroma formation and promoting myelination. 125 netrins The netrins are a recently described family of factors that are present on myelinated axons. Netrin-1 and its receptor DCC (deleted in colorectal cancer) are present on axons and myelinating oligodendroglia, respectively, 119, 126 and might be involved in glial recruitment and myelination. 119, 127 The absence of Dcc and Netrin in mice did not preclude myelination, but caused disruption of paranodal junctions. 128 Since these junctions are disrupted early in demyelinating diseas es, activation of netrin-1 could be protective.
evidence exists for functional or physical interactions between laminins, semaphorins and netrins. 129 Thus, these molecules might represent common pharmacological targets for combined therapies that aim to promote both remyelination and axonal regeneration.
Orphan receptors and signals
A few molecules have been shown to modulate my elination and probably mediate axoglia interactions, but their relationships to established ligands, receptors or signaling pathways are unclear.
Serum response factor
In the nervous system, serum response factor (SRF)-an immediate-early gene response transcription factor-is important for axonal pathfinding 130 and nerve growth factor-dependent innervation of sensory neurons. 131 Surprisingly, selective ablation of Srf in neurons of mice led to hypomyelination (primarily around large-caliber axons), impairment of oligodendroglial development and an increase in astrocyte numbers. 132 lack of SRF augments 133 In this study, these researchers found evidence that GPR126 acts in Schwann cells to increase cylic AMP levels, activate the zebrafish homolog of eGR-2 and promote myelination. The ligand for GPR126 has not yet been identified, and the downstream effects of activating GPR126 in the CNS remain to be described, although the mammalian homolog of this receptor is under study in mice.
Activation of GPR17, a P2Y purinergic GPR, provides inhibitory regulation of myelination. Mice with loss-offunction mutations in Gpr17 showed premature myelination, whereas overexpression of this gene in mouse brain or cultured OPCs inhibited the maturation of OPCs to myelinating oligodendrocytes, at least in part by increasing ID-2 and ID-4 expression in the nuclei of OPCs. 134 Interestingly, pharmacological activation of GPR17 augmented maturation and myelin basic protein expression in cultured OPCs. 135 Contrasting results notwithstanding, these data suggest that GPR17 might participate in the purinergic receptor-regulated timing of oligodendroglial differentiation, which was previously postulated by Fields and colleagues 23 to couple electrical activity to the onset of myelination. Furthermore, GPR17 is upregulated in demyelinating lesions in eAe and MS, making this receptor another candidate target for derepression of OPC di fferentiation in MS.
Wnt signaling
In both the CNS and PNS, glial cells must exit from the cell cycle to differentiate and to initiate the myelination program. This transition is regulated at the transcriptional level 65, 68 and, at least in the CNS, requires histone deacetylation, 136 which in part inhibits the Wnt ( wingless-related mouse mammary tumor virus integration site protein) signaling pathway. 137 One of the molecules implicated in controlling the exit from the cell cycle is the transcription factor YY1 (yin and yang 1). 138 This highly conserved nuclear protein can act either as a repressor or activator of transcription. 139 Conditional ablation of Yy1 in oligodendrocytes in mice led to impairment of myelination, particularly in the spinal cord. This phenotype was accompanied, at the molecular level, by an arrest of differentiation, with OPCs blocked after exit from the cell cycle. This block was probably the result of a loss of recruitment of YY1 and repressive HDACs to the promoters of transcriptional inhibitors such as transcription factor 4 (TCF4) and ID-4. 138 The consequence of such changes would be uncontrolled inhibition of OPC terminal differention.
The model of derepression of transcriptional inhibitor expression outlined above was further supported by the observations that the Wnt-catenin β1 signaling pathway was shown to be active in oligodendroglia surrounding MS lesions, and that dysregulation of these signals in OPCs delayed myelination and remyelination. 140, 141 Surprisingly, Tcf4-null mice, which might have been predicted to show derepression from Wnt signaling and premature myelination, actually showed a reduction rather than an increase in expression of oligodendrocyte terminal differentation genes. Myelination could not be directly assessed in this study as Tcf4-null mice die perinatally. 142 Ablation of the genes encoding components of the Wnt-catenin β1-TCF4 signaling pathway in oligodendrocytes during myelination will be required to fully understand the role of this pathway in this process, and its therapeutic potential. 68, 176 and mutations in the genes encoding these proteins are associated with Charcot-Marie-Tooth neuropathies, 9 Waardenburg-Hirschsprung disease and central dysmyelination. 65, 177 SOX-2, AP-1 (in part comprising cJun) and inhibitor of DNA binding 4 (not shown) are inhibitory transcription factors that are active before myelination. The inappropriate activation of these factors might be harmful in neuropathies. 6 Abbreviations: AKT1, serine-threonine-specific protein kinase AKT-PKB; AP-1, activator protein 1; cAMP, cyclic AMP; CN, calcineurin; EGR-2, early growth response protein 2; GPR, G protein-coupled receptor; IGF-I, insulin-like growth factor I; IGF-IR, IGF-I receptor; NECL, nectin-like protein; NFATc4, nuclear factor of activated T cells, cytoplasmic 4; NICD, Notch 1 intracellular domain; P2, purinergic 2 receptor; PAR3, partition defective 3; PI3K, phosphatidylinositol 3 kinase; PLC, phospholipase C; POU3F1, POU domain class 3 transcription factor 1; SOX, SRY-box containing transcription factor; SREBP , sterol regulatory element binding protein.
revieWS

Does myelination model remyelination?
Many signaling molecules have been characterized for their involvement in myelin formation during development, but only a limited number of these have been evaluated in the context of remyelination. Nevertheless, in a few cases, some molecules have been found to only have a role in myelination or remyelination, while others have been found to have opposing effects in these processes. Thus, it is too early to judge whether signaling molecules generally behave in a similar way in both development and myelin repair. As Franklin and ffrench-Constant have reviewed, 13 these findings might suggest that the intrinsic mechanisms underlying myelin formation in development and after damage differ from one another. Alternatively, contrasting roles of the signaling molecules might stem from the specific inhibitory characteristics of the demyelinating environment (for example, inflammatory cytokines), which are not present during development. Moreover, disparate effects might be explained by the fact that comparisons are being drawn between diverse processes (for example, comparison of the effects on migration in development with effects on differentiation in demyelination) or, more simply, by experimental issues (for example, genetic ablation of one gene might induce compensatory expression of other genes).
One example of a molecule that behaves differently in development and remyelination is oligodendrocyte transcription factor 1 (OlIG1), which is a transcription factor that is important for the production and differen tiation of OPCs, as well as for myelination. Studies in Olig1-null mice suggested that OlIG1 is much less important in developing oligodendrocytes than in remyelinating oligodendrocytes. 143 Xin and colleagues, however, found that OlIG1 was crucial for normal oligodendrocyte development and myelination. 144 This discrepancy is probably a consequence of different gene targeting strate gies. The st rategy used in the first study 143 might have activated transcription from the nearby Olig2 gene, which encodes another transcription factor that is essential for oligodendrocyte development and myelination. 144 Thus, multiple strategies to assess function, as well as testing in various models of demyelination, will be required to validate pu tative potentiators of myelin repair. 145 
Preclinical and clinical trials
Two types of therapeutic strategy related to myelination signals have been proposed. The first involves reducing the degree of interruption of myelination signals. As noted above, interruption of such signals is posited to occur at all levels of signaling pathways, ranging from extracellular ligand-receptor interactions 101, 146 to transcription. 6 Genetic proof of principle experiments are underway in mouse models of hereditary neuropathies to limit expression of 'dedifferentiation' genes such as cJun or Sox2 in Schwann cells, although no results have been published to date.
The second approach is to restore or augment normal myelination signaling during remyelination. The first preclinical and clinical trials along these lines have appeared in the last 6 years. Charcot-Marie-Tooth disease type 1A (CMT1A), which accounts for 70% of cases of hereditary demyelinating neuropathies, is caused by overexpression of peripheral myelin protein 22 (PMP22). Thus, a reduction in myelination signaling might normalize PMP22 expression and be of therapeutic benefit in such diseases. Preclinical trials of ascorbic acid (which might lower levels of cAMP) 147, 148 and the progesterone inhibitor onapristone 149, 150 have demonstrated that, in principle, reduction of PMP22 levels improves myelination in animal models of CMT1A. As a result, several clinical trials of ascor bic acid in patients with CMT1A are underway [151] [152] [153] and a search is ongoing for less-toxic progesterone in hibitors than onapristone. 154 Thyroid hormone T4 promotes oligodendrocyte differen tiation and myelination during development, and has been shown to promote myelin repair in a pre clinical trial in acute eAe. 155 IGF-I also augments myelination in the CNS, 59 and a phase II pilot study of the tolerability and efficacy of subcutaneously administered recombinant human IGF-I (CeP-151) in patients with MS has been completed, although no results have yet been reported.
Conclusions
Continuous reciprocal dialog between axons and myelinating glia is important during development and maintenance of the myelin sheath. various types of molecules, acting at diverse regulatory levels, mediate these events. Some of these signaling molecules normally promote myelination, and might be perturbed in myelin diseases, whereas others normally inhibit myelination and can be inappropriately active in such disorders. On the basis of these signals, several therapies are being examined in preclinical trials, and the first clinical trials are now underway.
The search for signaling molecules that promote remyelination holds promise for eventually developing combinatorial therapies, which incorporate existing antiinflammatory interventions, for demyelinating diseases. Future research into the development of such treatments must address two additional issues. First, for the various diseases of myelin, the initial site of damage (glia or axons) needs to be resolved, as this location might have consequences for where the drug is delivered. Indeed, the cell bodies of neurons and glia that form one myelin-axon unit sometimes reside in different parts of the nervous system (for example, Schwann cells in peripheral nerves versus motor neurons in the spinal cord) that are characterized by differing pharmacological barriers. Second, as evidence mounts for the important role of axonal injury in disability, glial signals that mediate axonal support need to be identified and characterized (Box 4). Surprisingly little is known about these signals currently.
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